Gregory W. Matz
Gregory W. Matz's purchase track record
Gregory W. Matz has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/15/2023 | OSS | $4K | +14.1% | +21.5% | +11.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
OSS Secures $1 Million Follow-On Defense Order. One Stop Systems announced a $1 million follow-on production order from a major defense and intelligence contractor. This contract supports the company's ongoing operations in the defense sector. The stock is currently trading near its 52-week low, with analysts maintaining an average price target of $19.00.
Transaction History
| DARE | ▲ Buy | Grant | 30,805 | $0 | 6/30/2026 | View on chart |
| OSS | ▼ Sell | Open Market | 8,000 | $140K | 5/26/2026 | View on chart |
| OSS | ▲ Buy | Grant | 11,984 | $0 | 5/20/2026 | View on chart |
| OSS | ▲ Buy | Grant | 21,000 | $0 | 5/21/2025 | View on chart |
| OSS | ▲ Buy | Grant | 21,000 | $0 | 7/1/2024 | View on chart |
| OSS | ▲ Buy | Open Market | 2,500 | $4K | 8/15/2023 | View on chart |
| OSS | ▲ Buy | Grant | 13,100 | $0 | 3/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
DARE Receives New Patents for HPV and Cervical Treatments
Dare Bioscience announced it has secured a U.S. patent for its HPV treatment program, which could position the company as a first pharmacologic option for HPV infection. The company also received a patent covering topical formulations of lopinavir and ritonavir for cervical pathologies. These approvals strengthen the company’s pipeline and may support future regulatory progress.
DARE Receives New Patents for HPV and Cervical Treatments. Dare Bioscience announced it has secured a U.S. patent for its HPV treatment program, which could position the company as a first pharmacologic option for HPV infection. The company also received a patent covering topical formulations of lopinavir and ritonavir for cervical pathologies. These approvals strengthen the company’s pipeline and may support future regulatory progress.